A Study Evaluating Ultratrace Iobenguane I 131(MIBG)in Patients With Malignant Pheochromocytoma/Paraganglioma
Conditions: Paraganglioma; Pheochromocytoma;
ClinicalTrials.gov Identifier: NCT00874614

Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Conditions: Paraganglioma; Pheochromocytoma;
ClinicalTrials.gov Identifier: NCT00911729

Iodine I 131 Metaiodobenzylguanidine and Arsenic Trioxide in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Conditions: Neuroblastoma; Pheochromocytoma;
ClinicalTrials.gov Identifier: NCT00107289

Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma; Paraganglioma
ClinicalTrials.gov Identifier: NCT00458952

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors; Gastrointestinal Carcinoid Tumor;
Islet Cell Tumor; Pheochromocytoma; Sarcoma;
ClinicalTrials.gov Identifier: NCT00049023

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Conditions: Head and Neck Cancer; Multiple Endocrine Neoplasia 1 and 2 (men1, men2)
ClinicalTrials.gov Identifier: NCT00390325

Treatment of Zollinger-Ellison Syndrome With Prevacid
Conditions: Zollinger-Ellison Syndrome; Multiple Endocrine Neoplasia
ClinicalTrials.gov Identifier: NCT00204373

Vandetanib in Treating Young Patients With Medullary Thyroid Cancer
Conditions: Head and Neck Cancer; Multiple Endocrine Neoplasia 1 and 2 (men1, men2)
ClinicalTrials.gov Identifier: NCT00514046